Dr. Tom W. Chen is an attending physician at the Department of Oncology, National Taiwan University Hospital (NTUH) in Taipei, Taiwan. Dr. Chen received internal medicine training followed by a fellowship course as a medical oncologist in NTUH. Afterwards, he joined Drug Development Program (DDP) in Princess Margaret Cancer Centre in Toronto, Canada as a clinical fellow to study early phase clinical trials with Dr. Lillian Siu and Dr. Phil Bedard. After returning to NTUH, he facilitated the establishment of sarcoma multi-disciplinary team. He is actively involved in many global sarcoma clinical trials as well as investigator-initiated clinical trials in soft tissue sarcoma. He is the PI of the LEADER study, which tests the combination of lenvatinib and eribulin in leiomyosarcoma and liposarcoma and the abstract was selected for oral presentation in the ASCO 2020 Virtual Meeting. He also collaborated with the Dr. Wolf Fridman and Catherine Sautes-Fridman of the Cordelier Research Center in Paris to investigate the immune microenvironment of soft tissue sarcoma. The collaborative research demonstrated the importance of B cells and tertiary lymphoid structure in soft tissue sarcoma was published in Nature. He also actively participated in many international sarcoma groups including Asia Sarcoma Consortium and World Sarcoma Network. He was appointed the Sarcoma Scientific Chair of ESMO Asia 2019 and more recently Sarcoma Scientific Chair of ESMO 2022.